Benjamin H. Lowentritt, MD, FACS

United Urology Group

Baltimore, Maryland

Benjamin H. Lowentritt, MD, FACS, is Director of Prostate Cancer Services for United Urology Group, the leading network of urologists in the United States. He previously served as the Director of the Prostate Cancer Care Program and Director of Minimally Invasive Surgery and Robotics at Chesapeake Urology, one of United Urology’s group practices. Dr. Lowentritt is also a member of United Urology’s Executive Clinical Team.

Dr. Lowentritt earned his medical degree from Baylor College of Medicine in Houston, Texas. He completed his medical residency at the University of Maryland School of Medicine and a fellowship in robotic, laparoscopic, and endoscopic urology at Tulane University. He has served on the board of the Mid-Atlantic Section of the American Urological Association, as well as on the Boards of Directors for MedChi, the Maryland State Medical Society, and the Baltimore City Medical Society.

Disclosures:

Abstract Commentary:Association Between Patient-Reported Outcomes and Changes in Prostate-Specific Antigen in Patients with Advanced Prostate Cancer Treated with Apalutamide in the Spartan and Titan Studies

Posted by Benjamin H. Lowentritt, MD, FACS | Jul 2022

Benjamin H. Lowentritt, MD, FACS, presented this lecture during the 32nd Annual International Prostate Cancer Update on March 8, 2022, in Snowbird, Utah.

Benjamin H. Lowentritt, MD, FACS

United Urology Group

Baltimore, Maryland

Talks by Benjamin H. Lowentritt, MD, FACS

Abstract Commentary:Association Between Patient-Reported Outcomes and Changes in Prostate-Specific Antigen in Patients with Advanced Prostate Cancer Treated with Apalutamide in the Spartan and Titan Studies

Join the GRU Community

You have Successfully Subscribed!

Benjamin H. Lowentritt, MD, FACS

United Urology Group

Baltimore, Maryland

Talks by Benjamin H. Lowentritt, MD, FACS

Abstract Commentary: Association Between Patient-Reported Outcomes and Changes in Prostate-Specific Antigen in Patients with Advanced Prostate Cancer Treated with Apalutamide in the Spartan and Titan Studies

Join the GRU Community

You have Successfully Subscribed!

Abstract Commentary:Association Between Patient-Reported Outcomes and Changes in Prostate-Specific Antigen in Patients with Advanced Prostate Cancer Treated with Apalutamide in the Spartan and Titan Studies